Premium
Botulinum toxin therapy for palmar hyperhidrosis: experience in an Iranian population
Author(s) -
Aghaei Shahin
Publication year - 2007
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2007.02928.x
Subject(s) - medicine , citation , botulinum toxin , population , dermatology , family medicine , world wide web , surgery , computer science , environmental health
There seems to be a genetic predisposition to primary (essential) hyperhidrosis and it often manifests itself in childhood or puberty. Essential or focal hyperhidrosis characteristically does not occur during sleep, but is made worse by heat and emotional situations, as it is considered that the hypothalamic sweat centers are more sensitive to emotional stimuli in nonhyperhidrotic subjects. 2 However, it is estimated that 0.6–1.0% of the population suffers from primary (essential) hyperhidrosis and in many it can become chronic and can lead to significant disruption in both social and professional life, leading to a marked impact on the patient's quality of life (QoL). 2 Patients find the symptoms embarrassing and often complain that the anticipation of sweating leads to avoidance of certain activities. 3 Sweat rates are highly variable between individuals and are thought to be a factor of acclimatization, sex, age, and possibly diet. 4 The aim of the present study was to evaluate the effectiveness, safety, and adverse reactions of botulinum toxin type A, Dysport® (Speywood Pharmaceuticals, Berkshire, UK) on the patients with recalcitrant palmar hyperhidrosis.